Checkpoint immunotherapy for NK/T cell lymphoma—Time for a showdown?

作     者：Jason Yongsheng Chan Jing Quan Lim Choon Kiat Ong 

作者机构：Division of Medical OncologyNational Cancer Centre Singapore169610Singapore SingHealth Duke-NUS Blood Cancer Centre169610Singapore Lymphoma Genomic Translational Research LaboratoryDivision of Cellular and Molecular ResearchNational Cancer Centre Singapore169610Singapore Duke-NUS Medical School169857Singapore Genome Institute of Singapore138672Singapore 

出 版 物：《Precision Clinical Medicine》 (精准临床医学（英文）)

年 卷 期：2021年第4卷第1期

页      面：70-72页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：immune checkpoint inhibitor chemoimmunotherapy PD-1 nasal lymphoma 

摘      要：Editor’s note A commentary on“Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.Extranodal natural killer/T-cell lymphoma(ENKTL)is an uncommon and aggressive subtype of non-Hodgkin lymphoma with a geographic distribution unique to East Asia and Latin America.